Join our pre-Series A round to fund our dry AMD program
SeaBeLife is currently finalizing its pre-Series A funding round, targeting a total of €2 million. The goal is to finance … Lire la suite
News
SeaBeLife receives Orphan Drug Designation (ODD) from EMA for treatment of acute liver injuries
Download pdf Orphan designation shows recognition of therapeutic potential of drug candidate SBL01 targeting two regulated cell death pathways … Lire la suite
27th Carrés 2023 – SEABELIFE Innovation Award
For the 27th edition of the “Soirée des Carrés”, the Morlaix region’s business club, Domaine de Treuscoat, SeaBeLife and La … Lire la suite
LSX Inv€$tival Showcase
📢 SeaBeLife Biotech will be attending the 8th annual LSX Inv€$tival Showcase Morgane Rousselot, our founder and CEO, and @Jean-Pierre … Lire la suite